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Genomic instabilityChk1 plays a key role in the DNA replication checkpoint and in preserving genomic integrity. Previous studies
have shown that reduced Chk1 function leads to defects in the checkpoint response and is closely associated
with tumorigenesis. Here, we report that glucose deprivation caused the degradation of Chk1 protein without
perturbing cell cycle progression. The induction of Chk1 degradation in response to glucose deprivation was
observed in various cancer cell lines and in normal human ﬁbroblasts. Therefore, it appears to be a universal
phenomenon in mammalian cells. A speciﬁc proteasome inhibitor blocked glucose deprivation-induced Chk1
degradation. Ubiquitination of Chk1 was detected, indicating that the proteasome–ubiquitin pathway
mediates Chk1 degradation upon glucose deprivation. Mechanistic studies have demonstrated that ATR-
dependent phosphorylation of Chk1 at the Ser317 and Ser345 sites is not required, suggesting that the
molecular mechanism for Chk1 degradation upon glucose deprivation is distinct from genotoxic stress-
induced degradation. Under conditions of glucose deprivation, the cells manifested a defective checkpoint
response to replication stress, camptothecin or hydroxyurea. The forced expression of Myc-Chk1 partially
rescued the defective response to the replication block upon glucose deprivation. Taken together, our results
indicate that glucose deprivation induces ubiquitin-mediated Chk1 degradation and defective checkpoint
responses, implying its potential role in genomic instability and tumor development.ry, College ofMedicine, Dong-A
402919.
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Faithful DNA replication and segregation are essential steps for
normal cell growth and the maintenance of genomic integrity.
Mammalian cells have conserved checkpoint pathways to ensure
accurate DNA replication and to monitor DNA damage [1]. The ATM-
Chk2 and ATR-Chk1 pathways represent major checkpoints that
respond to a stalled replication fork or DNA damage and regulate
various cellular responses, including cell cycle arrest, DNA repair, and
apoptosis [2]. Inactivation of checkpoint pathways or suppression of
important checkpoint regulators, including Chk1 and Chk2, frequently
results in tumorigenesis or induces malignant tumor progression [2–4].
Chk1 was ﬁrst identiﬁed in ﬁssion yeast as an essential kinase
involved in DNA damage-induced cell cycle arrest [5]. Subsequent
studies revealed that Chk1 also plays a critical role in the cellularresponse to genotoxic stresses in other organisms, including Xenopus
and the mouse as well as in human cells [6]. Studies also revealed that
Chk1 function is essential for maintaining DNA replication check-
points in unperturbed cell cycles. Fission yeast cells lacking Chk1
progressed to mitosis with unreplicated DNA [7,8]. Mouse embryos
and embryonic stem (ES) cells lacking Chk1 exhibited defective
checkpoint responses to replication blocks [6,9]. More importantly, a
recent study demonstrated that Chk1 heterozygosity (Chk+/−)
induced abnormal cell cycle coordination caused by defective DNA
replication [10]. These studies have established that Chk1 plays a
pivotal role in normal cell cycle control and that maintaining proper
Chk1 levels is essential to DNA integrity and tumor suppression.
In response to replication blocks or DNA damage, Chk1 is activated
mainly by the upstream PI-3 kinase, ATR, through phosphorylation at
Ser317 and Ser345 [6,11]. The activated Chk1 phosphorylates
downstream targets cdc25A and cdc25C and thereby induces cell
cycle arrest at the S and G2/M phases, respectively [2]. After DNA
repair is completed, the checkpoint signaling must be terminated to
return cells to a homeostatic state. Previous studies have shown that
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ylate activated Chk1 and promote termination of the checkpoint
response [12–14]. In addition to Chk1 deactivation through dephos-
phorylation, recent studies have shown that Chk1 is deactivated
through proteolytic degradation upon genotoxic treatment and
replication stress [15–19]. Interestingly, these studies revealed that
the phosphorylation of Chk1 at Ser 317 and Ser345 not only promotes
full activation of Chk1, but also induces degradation of Chk1 through
the ubiquitin–proteasome pathway. These studies indicated that Chk1
function is strictly regulated through complicated activation and
inactivation pathways that maintain proper cell proliferation and DNA
integrity. Therefore, it is not surprising that abrogation of normal
Chk1 function is a critical step for tumorigenesis or tumor progression
[1,2]. Given the essential role of Chk1 in normal cell growth and
tumorigenesis, unveiling how Chk1 function is suppressed during
tumorigenesis and tumor development is an important issue.
Glucose concentrations are strictlymaintained at about 5 mMunder
physiological conditions, but glucose deprivation develops under
conditions in which the blood supply is restricted such as in tissue
ischemia and solid tumors [20,21]. Previous studies have shown that
glucose concentrations are decreased to less than 2 mM within solid
tumor masses [20,22,23]. The tumor microenvironment has been
implicated as an inducer of genomic instability and tumor progression
[24–26]; however, the effect of glucose deprivation on checkpoint
function is largely unknown. In this report, we describe our ﬁnding that
Chk1 stability is regulated in a glucose concentration-dependent
manner. Our data suggest that glucose deprivation induces Chk1
degradation through the ubiquitin–proteasome pathway and induces
defective checkpoint responses in response to replication blocks.
2. Materials and methods
2.1. Cell culture, glucose deprivation and reagents
A549, HEK293, U2OS, Hela, HepG2, and IMR90 cell lines were
maintained in DMEM-high glucose media (Invitrogen) containing
4 mM glutamine and 10% fetal bovine serum (FBS) (Invitrogen,
Carlsbad, CA). For glucose deprivation, cells were washed three times
with DPBS and replaced with glucose-free DMEM (Invitrogen)
containing 4 mM glutamine and 10% dialyzed FBS. To expose cells to
low glucose conditions, sterile glucose solution (0.2 g/ml) was added
into the medium at the desired ﬁnal concentration.
Cycloheximide (CHX), MG132, camptothecin (CPT), hydroxyurea
(HU), and caffeine were purchased from Sigma-Aldrich Co. (St. Louis,
MO). Wortmannin was purchased from Calbiochem (San Diego, CA).
2.2. Western blot analyses and antibodies
Cells harvested after treatment were lysed in RIPA buffer and
subjected to western blot analyses, as previously described [27].
Antibodies for Chk1 (G-4), ubiquitin (P4D1), and Myc (9E10) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
for Chk2 (Clone-7) were obtained from Upstate (Billerica, MA).
Antibodies for phospho-Chk1 (S317), phospho-Chk1 (S345), phospho-
Chk2 (T68), and ATR were obtained from Cell Signaling Technology Inc.
(Danvers, MA). Actin levels were monitored as internal loading controls
using anti-actin (Sigma) antibodies. The western blot analyses were
repeated three times. Band intensities were quantiﬁed by densitometry
using AlphaEaseFC 4.0 software (Alpha Innotech). Relative band
intensities were calculated based on the band intensity of untreated
samples after normalization to the actin signal.
2.3. Synchronizations and cell cycle analyses
To synchronize A549 cells to G1/S boarder, sub-conﬂuent cells
were treated with 2 mM thymidine for 16 h and released by washingthree times with pre-warmed PBS. After grown for 10 h in complete
medium, 2 mM thymidine was added again and the cells were
cultured for an additional 16 h. Cells were washed with PBS and
released into complete medium containing an indicated concentra-
tion of glucose. To synchronize at G0 phase, A549 cells were cultured
in the medium containing 0.1% FBS for 72 h and released into serum-
enriched media.
To determine the cell cycle distribution, 1×106 cells were seeded
into a 100 mm dish. After glucose deprivation treatments, cells were
trypsinized at various time points and ﬁxed with 70% ethanol.
Subsequently, cells were stained with propidium iodide (PI), and
analyzed by ﬂow cytometry using EPICS XL cytometer and WINCYCLE
software (Beckman Coulter Inc.). A total of 10,000 events were
analyzed for each sample, and the experiment was repeated at least
twice.2.4. Semi-quantitative RT-PCR analyses
For semi-quantitative reverse transcriptase (RT)-PCR analyses, total
RNA was isolated using TRIZOL reagent (Invitrogen) according to the
manufacturer's instructions. The cDNA was obtained using Moloney
murine leukemia virus reverse transcriptase (MMLV-RT) and oligo-dT
primers (Promega, Madison, WI). PCR was carried out with Accupower
PCR premix (Bioneer Co., Taejon, Korea) using cDNA as template. PCR
products were separated by 2% agarose gel electrophoresis. PCR
conditions were as follows: one cycle at 95 °C for 5 min, followed by
25 cycles at 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s. The primers
employed in RT-PCR were as follows: Chk1 forward primer 5′-
CTTTGGCTTGGCAACAGT-3′, Chk1 reverse primer 5′-CCAGTCAGAA-
TACTCCTG-3′, Chk2 forward primer 5′-GCGCCTGAAGTTCTTGTTTC-3′,
Chk2 reverse primer 5′-GCCTTTGGATCCACTACCAA-3′, actin forward
primer 5′-CAAGAGATGGCCACGGCTGCT-3′, and actin reverse primer 5′-
TCCTTCTGCATCCTGTCGGCA-3′. Experiments were repeated at least
three times.2.5. Plasmids, transfection and establishment of cell lines
An expression plasmid encoding Flag-Chk1was kindly provided by
Dr. Yolanda Sanchez (University of Cincinnati, Cincinnati, OH). The
HA-tagged ubiquitin expression plasmid (HA-pCS2-FA-Ub) has been
previously described [28]. Expression plasmids encoding Myc-tagged
wild-type, S317A, and S345A Chk1 were kindly provided by Dr. Helen
Piwnica-Worms (Washington University, St. Louis, MO). DNA trans-
fections were performed using Lipofectin reagent (Invitrogen)
according to the manufacturer's instructions. To generate HEK293
cells stably expressingMyc-Chk1wild type, S317A, and S345mutants,
the pcDNA3 control vector orMyc-Chk1 plasmidwere transfected and
cells were selected with 500 μg/ml of neomycin for 2 weeks. After
selection, resistant cells were pooled and the expression of Myc-Chk1
was conﬁrmed by western blotting.2.6. Ex vivo ubiquitination assays
Chk1 ex vivo ubiquitination assays were performed as previously
described [28]. Brieﬂy, A549 or HEK293 cells were transfected with
10 μg of expression plasmid for Flag-tagged Chk1 and HA-ubiquitin.
After 24 h, the cells were exposed to glucose deprivation together
with MG132 (10 μM) or DMSO vehicle for 16 h, lysed with sodium
dodecyl sulfate (SDS) buffer, and boiled for 5 min. The extracts were
diluted 10-fold with buffer A containing proteasome inhibitors and
10 mM N-ethylmaleimide (Sigma) and then immunoprecipitated
with anti-Flag or anti-Myc antibodies. The immunoprecipitated
protein was immunoblotted with anti-ubiquitin antibodies. Experi-
ments were repeated at least three times.
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An siRNA pool speciﬁc for ATR (ON-TARGETplus SMARTpool
Human ATR, L-003202000005) and control siRNA (ON-TARGETplus
Not-targeting siRNA, D-0018100105) were obtained from Dharmacon
(Lafayette, CO). To knockdown ATR expression, A549 cells (4×105)
were seeded into a 60-mm dish and siRNA was transfected using
DharmaFECT1 transfection reagent (Dharmacon) according to the
manufacturer's instructions.
2.8. Fluorescence micronucleus analysis
Cells were grown on cover slides and ﬁxed with 3% paraformalde-
hyde for 10 min at room temperature. Cells were then permeabilized
with 0.2% Triton X-100 and stained with DAPI (4,6-diamino-2-
phenylindole, Sigma). The nucleuswas examined at 200×magniﬁcation
using a ﬂuorescencemicroscope (Olympus BX50F, Olympus Optical Co.
Ltd, Tokyo). After capturing nuclear images by CCD camera (Olympus
DP70), 200 to 500 cells for each sample in several ﬁelds were examined
and the number of micronucleated cells or multinucleated cells was
counted.
3. Results
3.1. Glucose deprivation cause a reduction in Chk1protein levels
Over the course of our studies on Chk1 function, we observed that
Chk1 levels were signiﬁcantly reduced under low glucose conditions.
To investigate the effect of glucose concentration on Chk1 function,
we ﬁrst examined Chk1 protein levels in A549 cells that had been
exposed to various concentrations of glucose for 12 h. We found that
the amount of Chk1 was signiﬁcantly decreased when cells were
cultured in medium containing less than 2 mM glucose compared to
normal physiological glucose levels (5 mM), but high glucose
concentrations (10 mM) did not inﬂuence Chk1 levels (Fig. 1A). A
time-course study revealed that the amount of Chk1 was reduced to
less than 10% by 12 h after glucose deprivation (0 mM) (Fig. 1B).
Conversely, levels of Chk2, another important checkpoint kinase, were
not changed under any of the glucose concentration conditions tested.Fig. 1. Chk1 protein levels are regulated by glucose concentration. (A) A549 cells were
cultured for 12 h in media containing various concentrations of glucose (Glu) and
harvested. Cell lysates were subjected to western blotting using anti-Chk1, anti-Chk2
and anti-actin antibodies. B–D. A549 cells were exposed to glucose deprivation (GD,
0 mM) conditions and harvested at the indicated time points for western blotting (B),
and RT-PCR (C). RT-PCR analyses were performed as described in the Materials and
methods. (D) A549 cells were cultured for 12 h in 10 mM glucose (−) or 0 mM glucose
(+). A549 cells exposed to glucose deprivation were then changed to high glucose
(10 mM) media and subsequently cultured for an additional 24 h. Cell lysates were
subjected to western blotting. The data shown are representative of three independent
experiments.Semi-quantitative RT-PCR results showed that Chk1 mRNA levels
were unchanged following glucose deprivation (0 mM) (Fig. 1C),
suggesting that the reduction in Chk1 upon glucose deprivation is
regulated by a posttranscriptional mechanism. A similar reduction in
Chk1 protein levels, without changes in Chk1 mRNA levels, following
glucose deprivation (0 mM) was also observed in HEK293 cells
(Supplementary Fig. S1A and B). The reduction in levels of Chk1 upon
glucose deprivation was restored by re-addition of glucose (Fig. 1D),
suggesting that Chk1 protein levels are reversibly regulated by
glucose concentration.
3.2. Chk2 levels are decreased by glucose deprivation independently of
an effect on cell cycle
Chk1 levels are regulated in a cell cycle-dependent manner [29,30].
Because glucose deprivation often induces cell cycle arrest and cell
death, we examined whether Chk1 reduction following glucose
deprivation results from altered cell cycle distribution or cell death.
Cell cycle analyses after glucose deprivation (0 mM) showed no
signiﬁcant changes in A549 cells until at least 18 h after glucose
deprivation (Supplementary Fig. S2). HEK293 cells also showed no
changes to the cell cycle proﬁle upon glucose deprivation (0 mM) until
18 h (Supplementary Fig. S1C). Cell proliferation assays employingA549
cells exposed to various glucose concentrations (from 10 mM to 0 mM)
showed that cell death was observed only when cells were cultured
with glucose concentrations below 0.2 mM. In addition, the cells
proliferated continuously, albeit growth rate is little bit decreased, at
glucose concentrations over 1 mM and showed no signs of cell death
(Supplementary Fig. S3A). However, in 1 mM and 2 mM glucose
condition, decreased Chk1 protein levels were evident (Supplementary
Fig. S3B).
To avoid possible complications of glucose deprivation on cell cycle
progression, we synchronized A549 cells at the G1/S border by double
thymidine block and released the cells into a medium containing high
glucose (10 mM) or glucose deprivation conditions (1 mM). Whereas
cell cycle propagation after release from thymidine block was not
affected by glucose deprivation (Supplementary Fig. S4A), Chk1 levels
were signiﬁcantly reduced in cells exposed to glucose deprivation
conditions (Fig. 2A). Next, A549 cells were synchronized by serum
deprivation for 72 h. Consistentwith a previous study [29], Chk1 protein
was hardly detectable after serum starvation and increased 16 h after
serum stimulation (Fig. 2B). While cell cycle propagation was not
affected (Supplementary Fig. S4B), glucose deprivation inhibited the
increase in Chk1 level after serum stimulation (Fig. 2B). Using these
collective data, we concluded that the reduction of Chk1 protein
observed following glucose deprivation is not the result of either cell
cycle arrest or cell death.Fig. 2. Reduced Chk1 in response to glucose deprivation is cell cycle-independent. (A)
A549 cells were synchronized by double thymidine block and released into media
containing high glucose (10 mM) or glucose deprived (1 mM), as described in the
Materials and methods. Cell lysates were prepared at the indicated time points and
subjected to western blotting using anti-Chk1 and anti-actin antibodies. (B) A549 cells
were synchronized by culturing in 0.1% FBS medium for 72 h and subsequently
restimulated with 10% FBS containing high glucose (10 mM) or low glucose (1 mM).
Cell lysates were prepared at the indicated time points and subjected to western
blotting using the indicated antibodies. AS denotes asynchronous cells.
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To further conﬁrm that glucose deprivation induced Chk1
degradation and to avoid possible artifacts of using speciﬁc cell
lines, we examined Chk1 protein expression after glucose deprivation
in various cell lines. As shown in Fig. 2, the amount of Chk1 protein
was also signiﬁcantly decreased after 12 h of glucose deprivation
(0 mM) in all cancer cell lines examined, including HEK293, U2OS,
Hela, and HepG2 cells. Similarly, reduced levels of Chk1 following
glucose deprivation were also observed in normal lung epithelial
IMR90 cells. These results suggest that Chk1 degradation in response
to glucose deprivation is a universal phenomenon.
3.4. Chk1 protein stability is decreased upon glucose deprivation
Next, to investigate the molecular mechanisms by which glucose
deprivation causes reduction in Chk1 levels, we examined the half-life
of the Chk1 protein after glucose deprivation. To examine whether
Chk1 protein stability is modulated by glucose deprivation, we
measured Chk1 turnover rates under high glucose (10 mM) or
glucose deprivation conditions (0 mM) in the presence of a protein
synthesis inhibitor, cycloheximide. Consistent with a previous report
[19], we found that Chk1 has a half-life of approximately 4 h in 10 mM
glucose (Fig. 3). However, the half-life of Chk1 was decreased to less
than 2 h under glucose deprivation conditions (0 mM). These resultsFig. 3. Glucose deprivation leads to reduced Chk1 levels in various cell lines. Various
human cancer cell lines and the normal human lung epithelial cell line IMR90 were
exposed to glucose deprivation (GD; 0 mM) and harvested at the indicated time points.
Cell lysates were subjected to western blot analyses using anti-Chk1 and anti-actin
antibodies. The western blot analyses were repeated three times.indicate that glucose deprivation-induced downregulation of Chk1 is
due to degradation of Chk1 protein.
3.5. Chk1 is degraded through the ubiquitin–proteasome pathway in
response to glucose deprivation
Rapid protein degradation is usually mediated by the ubiquitin–
proteasome pathway [31,32]. To test whether Chk1 degradation is
mediated by this pathway in response to glucose deprivation, we
examined the effect of MG132, a potent proteasome inhibitor, on
Chk1 degradation in A549 and HEK93 cells under glucose deprivation
conditions. As shown in Fig. 4A and B, glucose deprivation-induced
Chk1 degradation was completely abolished by MG132 treatment in
A549 and HEK293 cells, respectively. In addition, MG132 treatment
completely inhibited glucose deprivation-induced degradation of
transiently expressed Flag-Chk1 (Fig. 4C).
Proteasome-dependent degradation usually requires ubiquitination
of the substrate protein for it to be recognized by the 26S proteasome
[33]. To examine whether Chk1 is ubiquitinated upon glucose
deprivation, we performed ex vivo ubiquitination assays using Flag-
Chk1. Following glucose deprivation (0 mM) in both A549 and HEK293
cells, immunoprecipitation with anti-Flag antibodies followed by
immunoblot analyses with anti-ubiquitin antibodies revealed the
presence of high-molecular-mass smears, which are a common
characteristic of polyubiquitinated proteins (Fig. 5D). Together, these
results suggest that Chk1 is ubiquitinated in response to glucose
deprivation and degraded by the 26S proteasome.
3.6. ATR-dependent phosphorylation at Ser317 and Ser345 is not
required for glucose deprivation-induced Chk1 degradation
Recent studies have reported that the phosphorylation of Chk1 by
ATR at Ser317 and Ser345 plays an important role in its ubiquitination
and degradation following various genotoxic stresses and replicationFig. 4. The half-life of Chk1 protein is decreased upon glucose deprivation. A549 cells
were cultured in either 10 mM or 0 mM glucose for 12 h. Cells were then treated with
cycloheximide (CHX) (50 μg/ml) and harvested at the indicated time points. Cell lysates
were subjected to western blotting using anti-Chk1 and anti-actin antibodies. Band
intensities were quantiﬁed by densitometry, and the band intensity values were
calculated relative to the band intensity of the 0 h sample after normalization to the
actin signal. The band intensity of Chk1 from the 0 h sample was deﬁned as 1.
Fig. 5. The ubiquitin–proteasome pathway mediates Chk1 degradation in response to glucose deprivation. (A) A549 cells were cultured in either 10 mM glucose or glucose
deprivation (GD) conditions (0 mM) in the presence or absence ofMG132 (10 μM) for 16 h. Cell lysates were subjected to western blotting using anti-Chk1 and anti-actin antibodies.
(B) HEK293 cells were cultured as in (A), and cell lysates were harvested at the indicated time points. Western blot analyses were performed using anti-Chk1 and anti-actin
antibodies. (C) HEK293 cells were transfected with a Flag-Chk1 plasmid and cultured as in (A). Cell lysates were subjected to western blotting using anti-Chk1 and anti-actin
antibodies. (D) A549 andHEK293 cells were transfected with Flag-Chk1 and HA-ubiquitin-expressing plasmids, and ex vivo ubiquitination assays were performed as described in the
Materials and methods under glucose deprivation (GD) conditions (0 mM). Cell lysates were immunoprecipitated with anti-Flag antibodies (M2) and immunoblotted with anti-
ubiquitin antibodies. The band corresponding to the immunoglobulin G heavy chain that reacts with the secondary antibody is labeled ‘IgG’ in the ﬁgure. Immunoprecipitated Flag-
Chk1 was also detected by immunoblotting with anti-Flag antibodies.
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ylation is important for glucose deprivation-induced Chk1 degrada-
tion, we ﬁrst examined Chk1 phosphorylation upon glucose
deprivation (0 mM) using anti-phospho antibodies speciﬁc for Chk1
phosphorylated at Ser317 and Ser345. Because Chk1 is rapidly
degraded upon glucose deprivation, protein lysate samples were
prepared in the presence of MG132 to examine Chk1 phosphorylation.
As shown in Fig. 6A, phosphorylation of Ser317 and Ser345was hardly
detected after glucose deprivation in contrast to phosphorylation after
UV irradiation, which is a representative genotoxic stress that induces
Chk1 phosphorylation [2].
If the phosphorylation of the Ser317 and Ser345 sites is important
for glucose deprivation-induced Chk1 degradation, then mutating
these sites should inhibit Chk1 ubiquitination and degradation upon
glucose deprivation. To test this possibility, we generated HEK293
cells stably expressing wild-type Myc-Chk1 or the S317A or S345A
mutants [11] and examined glucose deprivation-induced ubiquitina-
tion. We found that both Chk1 S317A and S345A mutants were
ubiquitinated in a manner similar to wild-type Chk1 (Fig. 6B).
Moreover, both Myc-Chk1 S317A and S345A mutants were degraded
upon glucose deprivation (0 mM) in a similar manner to wild-type
Chk1. The statistical analyses of three independent experiments
indicate that the extent of degradation was not statistically signiﬁcant
(pN0.05) (Fig. 6C). These results indicate that Chk1 phosphorylation
at Ser317 and Ser345 is not essential for glucose deprivation-
dependent degradation.
Consistent with these data, co-treatment with caffeine and
wortmannin, which are both potent chemical inhibitors of the ATR/
ATM-Chk1/Chk2 pathway, failed to inhibit glucose deprivation-
induced degradation of Chk1 (Fig. 6D). Moreover, speciﬁc suppression
of ATR expression by siRNA did not affect Chk1 degradation upon
glucose deprivation (0 mM) (Fig. 6E). These results indicate that the
glucose deprivation-induced degradation of Chk1 is independent of
ATR function. Thus, our data suggest that Chk1 is degraded through a
mechanism distinct from genotoxic stress-induced Chk1 degradation.3.7. Glucose deprivation induces a defective checkpoint response to DNA
replication blocks
Previous studies have demonstrated that reduced Chk1 function
induces a defect in cell cycle arrest and the checkpoint response upon
replication arrest andDNAdamage [9,10]. Our results show that glucose
deprivation results in decreased levels of Chk1 protein. Thus, we
expected that the cells would fail to execute normal checkpoint
responses to replication blocks in the glucose deprivation conditions.
To test this possibility, we examined the cellular checkpoint response
following replication blocks under both high glucose and glucose
deprivation conditions. HEK293 cells were cultured in high glucose
(10 mM) or glucose deprivation (1.5 mM) conditions for 12 h and
subsequently treated with camptothecin (CPT) or hydroxyurea (HU) as
a replication block. Cell cycle analyses showed that HEK293 cells were
arrested at the G1/S phase in response to CPT and HU treatments, and
these arrests were maintained until 48 h under high glucose conditions
(10 mM), indicating that the replication checkpoint pathway was
normally activated (Fig. 7A, Supplementary Table 1). Conversely, under
glucose deprivation conditions (1.5 mM), a portion of cells failed to
arrest at theG1/Sphase at24 h, andextensive cell deathwasobserved at
48 h after both CPT and HU treatments (Fig. 7A and B), suggesting that
the checkpoint response to the replication block was not properly
working due to the reduced level of Chk1 protein.Western blot analyses
conﬁrmed the reduced level of Chk1 protein in cells exposed to 1.5 mM
glucose and Chk1 activation levels were much lower than in the high
glucose condition, whereas Chk2 activationwas not affected by glucose
deprivation (Fig. 7C and D). Previous studies have shown that a
defective checkpoint response to genotoxic stress or the inactivation of
checkpoint genes often results in the formation of abnormal nuclear
structures such as micronuclei and multinuclei [34,35]. Fluorescence
microscopic analysis after staining cells with DAPI revealed that the
proportion of HEK293 cells that exhibited micronuclei or multinuclei
was profoundly increased 72 h after HU treatment in cells exposed to
the glucose deprivation conditions (1.5 mM) (Fig. 7E). These results
Fig. 6. ATR-dependent phosphorylation of Chk1 at Ser317 and Ser345 is not required for glucose deprivation-induced degradation. (A) A549 cells were exposed to glucose
deprivation (GD; 0 mM) in the presence of MG132 (10 μM) and harvested at the indicated time points. Cell lysates were analyzed by western blotting using the indicated antibodies.
A549 cell lysates harvested 2 h after UV irradiation (20 J/m2) were used as positive controls. (B) HEK293 cells stably expressing Myc-Chk1 wild type, S317A, or S345A were
transfected with a plasmid containing HA-ubiquitin, and ex vivo ubiquitination assays were performed as described in Fig. 5D using anti-Myc and anti-ubiquitin antibodies. (C)
HEK293 cells stably expressing Myc-Chk1 wild type, S317A, or S345A were cultured in 10 mM glucose or in glucose deprivation conditions (0 mM) for 16 h and harvested. Cell
lysates were analyzed by western blotting using the indicated antibodies. *pN0.05 as determined by Student's t-test. (D) A549 cells were exposed to glucose deprivation (GD; 0 mM)
and treated with 5 mM of caffeine or 5 μM of wortmannin for 16 h. Cell lysates were prepared and subjected to western blotting using the indicated antibodies. (E) A549 cells were
transfected with either negative control siRNA (NC) or siRNA against ATR (ATRi) as described in the Materials and methods. After 48 h, cells were cultured in 10 mM glucose or in
glucose deprivation conditions (0 mM) for 16 h and cell lysates were analyzed by western blotting using the indicated antibodies.
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of the replication checkpoint through ubiquitin–proteasome pathway
mediated Chk1 degradation and, in turn, results in an abnormal
checkpoint response to replication blocks.
To further conﬁrm that Chk1 degradation was responsible for the
defective checkpoint response in the glucose deprivation condition,
we examined whether Chk1 overexpression could ameliorate the
defects in response to replication blocks. To this end, we used HEK293
cells stably expressing Myc-Chk1 or control vector. While the
endogenous Chk1 level was remarkably reduced in the HEK293
vector control cells (vec), a considerable amount of Myc-Chk1 protein
remained in the glucose deprivation condition (1.5 mM) in HEK293-
Myc-Chk1 cells (Fig. 8A). Flow cytometry analysis showed that HU-
induced cell death in the glucose deprivation condition (1.5 mM) was
reduced in HEK293 Myc-Chk1 cells by about 30% (Fig. 7B). Moreover,
the proportion of the cells exhibiting micronuclei or multinuclei after
HU treatment was also decreased to about 50% (Fig. 7C), indicating
that Chk1 overexpression can rescue the defective checkpoint
response and cell death in glucose deprivation conditions. Taken
together, these results suggest that glucose deprivation induces
deactivation of the replication checkpoint through ubiquitin–protea-
some pathway-mediated Chk1 degradation and, in turn, results in an
abnormal checkpoint response to replication blocks.
4. Discussion
The present study reveals, for the ﬁrst time, that Chk1 protein
levels are regulated differently depending on the glucose concentra-
tion. First, we showed that the amount of Chk1 protein is signiﬁcantly
reduced in the presence of 2 mM or lower glucose as compared to
physiological glucose concentrations (Fig. 1A). Cell cycle analyses and
proliferation assay results demonstrated that Chk1 degradationoccurs prior to cell cycle arrest upon glucose deprivation and at
glucose concentrations that do not induce cell death (Supplementary
Fig. S1, S2 and S3). Cell synchronization experiments further
conﬁrmed that glucose deprivation induces Chk1 degradation
independently of its effect on cell cycle (Fig. 2).
The half-life of the Chk1 protein is dramatically decreased under
conditions of glucose deprivation, whereas levels of mRNA expression
are not changed (Fig. 1C and Supplementary Fig. S1). These ﬁndings
indicate that the Chk1 protein is rapidly degraded in response to
glucose deprivation. Consistent with endogenous Chk1, the ectopi-
cally expressed Flag-Chk1 andMyc-Chk1 proteins were also degraded
in response to glucose deprivation (Figs. 5C and 6C). Further analyses
using a proteasome inhibitor and ex vivo ubiquitination assays
demonstrated that Chk1 was degraded through the ubiquitination–
proteasome pathway (Fig. 5D). These results conﬁrm that the Chk1
protein is speciﬁcally downregulated in response to glucose depriva-
tion. The glucose deprivation-induced degradation of Chk1 was
observed in all cell lines tested (Fig. 3), suggesting that glucose
concentration-dependent control of Chk1 stability is a common
regulatory mechanism.
Recent studies show that Chk1 is ubiquitinated and degraded
through ATR-dependent phosphorylation at Ser317 and Ser345 upon
various genotoxic treatments [15,18,19]. Initially, we hypothesized
that ATR-dependent phosphorylation regulates Chk1 degradation
upon glucose deprivation. However, our results indicate that glucose
deprivation-induced Chk1 degradation is independent of ATR func-
tion. First, phosphorylation of Chk1 at Ser317 and Ser345 upon
glucose deprivation was barely observable compared to phosphory-
lation of Chk1 upon UV irradiation (Fig. 6A). Second, the S317A and
S345A Chk1 mutants are still ubiquitinated and degraded at a rate
comparable to wild-type Chk1 upon glucose deprivation (Fig. 6B and
C). Finally, glucose deprivation-induced Chk1 degradation was not
Fig. 8. Overexpression of Myc-Chk1 rescues the defective checkpoint response to replication blocks under glucose deprivation conditions. (A) HEK293 cells expressing Myc-Chk1 or
control vector (vec) were cultured in glucose deprivation conditions (1.5 mM) for 12 h and harvested. Cell lysates were subjected to western blot analyses using anti-Chk1 and anti-
actin antibodies. (B) HEK293 cells expressingMyc-Chk1 or control vector (vec) were cultured in 1.5 mMglucose for 12 h and treated with 1.5 mMof HU. Cells were harvested at 48 h
to determine the sub-G1 fraction (left panel) and at 72 h to determine the proportion of cells harboring micronuclei or multinuclei (right panel) as described in Fig. 7.
Fig. 7. Glucose deprivation induces defective checkpoint responses to replication blocks. (A) HEK293 cells were cultured in either 10 mM or 1.5 mM glucose for 12 h (0 h) and then
treated with 100 nM camptothecin (CPT) or 1.5 mM of hydroxyurea (HU). Cells were harvested at the indicated time points, stained with PI, and analyzed by ﬂow cytometry as
described in the Materials and methods. The data shown are representative of three independent experiments with similar results. (B) The percentage of cells in the sub-G1 phase
was determined using WINCYCLE software and plotted as the mean value with standard deviation. *pb0.05; **pb0.01 as determined by Student's t-test. (C) Protein levels of Chk1
and actin were determined in HEK293 cells cultured as in (A) and harvested at the indicated time point using anti-Chk1 and anti-actin antibodies. (D) HEK293 cells were cultured as
in (A) and harvested 2 h after CPT and HU treatment. Cell lysates were subjected to western blotting using anti-pS317 Chk1 (pChk1), anti-pT68 Chk1 (pChk2), and anti-actin
antibodies (E) HEK293 cells cultured on cover slides were treated with HU under high glucose (10 mM) or glucose deprivation conditions (1.5 mM) as in (A). After 72 h, Cells were
stained with DAPI and the cells with micronuclei or multinuclei were counted as described in the Materials and methods. A representative image of each sample is shown (left
panels). Arrows indicate micronuclei, and the arrowhead indicates a binucleated cell. Cells with micronuclei or multinuclei from the samples were plotted as the mean value in the
right panel.
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interference or inhibited by speciﬁc inhibitory compounds (Fig. 6D
and E). These results indicate that Chk1 is ubiquitinated and degraded
through a mechanism distinct from genotoxic treatment-induced
Chk1 degradation.
Our results suggest that Chk1 is ubiquitinated and degraded
through an ATR-independent pathway. In accordance with this
notion, Rodriguez-Bravo et al. showed that Chk1 is able to activate
and regulate cell cycle progression through an ATR-independent
mechanism in the presence of stalled replication forks [36].
Identiﬁcation of the E3 ubiquitin ligase responsible for Chk1
ubiquitination upon glucose deprivation would be helpful in
understanding the underlying mechanism of glucose deprivation-
induced degradation of Chk1. Several E3 ligases, such as Bmi1/Ring1A,
RNF182, and cullin-containing E3 ubiquitin ligase complexes, were
recently shown to be involved in protein degradation under glucose
deprivation conditions [37–40]. We are currently working toward
identifying the responsible E3 ubiquitin ligase. Further studies on
these topics would provide a better understanding of the precise
molecularmechanisms of glucose deprivation-induced degradation of
Chk1.
The results presented in this study suggest a possible link between
glucose deprivation and cellular checkpoint function. It has been
demonstrated that glucose deprivation conditions develop in solid
tumors. Due to architectural and functional abnormalities in the
capillary network, pronounced spatial heterogeneities in the meta-
bolic milieu exist in a solid tumor mass, and thereby, a number of
unique metabolic characters, such as hypoxia, low pH, and nutrient
starvation including glucose deprivation, are created [20,21]. Previous
studies have shown that glucose concentrations in some parts of solid
tumors are decreased to less than 1 mM [22,23,41]. Interestingly, it
has been proposed that the tumor microenvironment itself may be a
major cause of the genomic instability frequently observed in
malignant cancers [25,26]. Because these metabolic abnormalities
appear at early stages of tumor development as a consequence of
insufﬁcient blood perfusion [42], microenvironmental parameters
may inﬂuence cell cycle checkpoint control or DNA repair functions,
which are essential for maintaining genomic integrity. In accordance
with this notion, several recent studies have shown that factors within
the tumor microenvironment, such as hypoxia and low pH, may
contribute to genomic instability by increasing mutation frequencies
and diminishing DNA repair activities [25,43,44]. In addition to
hypoxia and low pH, glucose deprivation has also recently been
implicated in the induction of high mutation rates [45,46]. Consistent
with this report, we observed that cells show defective checkpoint
control under glucose deprivation conditions in response to replica-
tion blocks (Fig. 6). Moreover, ﬂuorescence microscopic observations
after staining with DAPI revealed that cells exhibiting abnormal
nuclear structures, such as micronuclei and multinuclei, were
substantially increased after HU treatments under glucose deprivation
(Fig. 6C and D). Abnormal nuclear structures, such as chromatin
bridges, micronuclei, and multinuclei, are known to be typical
phenotypes of chromosomal damage and genomic instability
[34,35]. Interestingly, Jardim et al. recently showed that reduced
Chk1 function resulted in abnormal nuclear structures, including
micronuclei and multinuclei [47]. Thus, it is possible to speculate that
glucose deprivation could promote genomic instability, at least in
part, through the degradation of Chk1 and subsequent abrogation of
checkpoint control. However, whether glucose deprivation indeed
induces spontaneous genomic instability and how glucose depriva-
tion-induced Chk1 degradation may contribute to this process remain
to be addressed in future studies.
In conclusion, this study reveals that Chk1 function is regulated by
proteasome-mediated proteolysis under glucose deprivation condi-
tions. Our results provide a possible explanation for how checkpoint
defects and genomic instability are induced in tumor microenviron-ments. Although the exact mechanism by which glucose deprivation
promotes the ubiquitination and degradation of Chk1 remains to be
explored, further studies will provide valuable information for
understanding the processes of tumor development, and they may
offer novel strategies for cancer treatment.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2011.03.012.
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